Michel Vulfovich, MD
Hematology & Oncology · Hollywood, FLNPI 1619185741
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,613 of the $1,686 with a category attached, or 95.6%. GSK accounts for 64.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $1,088, more than ten times the $74 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 3 payments — averaging $562.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$525
- Sirtex Medical Inc$74
Across 6 payments — averaging $20,590 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$124K
What the payments were for
- Consulting fees$1,61396%
- Food & beverage$744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $1,088 |
| AstraZeneca | 1 | $525 |
| Sirtex Medical Inc | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,686 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 29 | $68,490 |
| EliquisApixaban | 34 | $25,793 |
| XareltoRivaroxaban | 14 | $11,496 |
| Ondansetron Hcl | 35 | $4,389 |
| Prochlorperazine Maleate | 54 | $712 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 36 | $464 |
| Duloxetine Hcl | 31 | $448 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $441 |
| Ondansetron OdtOndansetron | 27 | $402 |
| Mirtazapine | 29 | $355 |
| Pantoprazole Sodium | 28 | $220 |
| Prednisone | 19 | $141 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hollywood
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.